Literature DB >> 29216348

MIC-based dose adjustment: facts and fables.

Johan W Mouton1, Anouk E Muller1,2, Rafael Canton3, Christian G Giske4, Gunnar Kahlmeter5, John Turnidge6.   

Abstract

Over recent decades, several publications have described optimization procedures for antibiotic therapy in the individual patient based on antimicrobial MIC values. Most methods include therapeutic drug monitoring and use a single MIC determination plus the relevant pharmacokinetics/pharmacodynamics to adjust the dose to optimize antimicrobial drug exposure and antibacterial effects. However, the use of an MIC obtained by a single MIC determination is inappropriate. First, routine clinical laboratories cannot determine MICs with sufficient accuracy to guide dosage owing to the inherent assay variation in the MIC test. Second, the variation in any MIC determination, whatever method is used, must be accounted for. If dose adjustments are made based on therapeutic drug monitoring and include MIC determinations, MIC variation must be considered to prevent potential underdosing of patients. We present the problems and some approaches that could be used in clinical practice.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29216348     DOI: 10.1093/jac/dkx427

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  72 in total

Review 1.  What Antibiotic Exposures Are Required to Suppress the Emergence of Resistance for Gram-Negative Bacteria? A Systematic Review.

Authors:  Chandra Datta Sumi; Aaron J Heffernan; Jeffrey Lipman; Jason A Roberts; Fekade B Sime
Journal:  Clin Pharmacokinet       Date:  2019-11       Impact factor: 6.447

2.  Personalized antibiotic dosing for the critically ill.

Authors:  Jason A Roberts; Claire Roger; Jan J De Waele
Journal:  Intensive Care Med       Date:  2019-01-14       Impact factor: 17.440

3.  On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.

Authors:  Claudio U Köser; Sophia B Georghiou; Thomas Schön; Max Salfinger
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

Review 4.  Aspergillus fumigatus and aspergillosis: From basics to clinics.

Authors:  A Arastehfar; A Carvalho; J Houbraken; L Lombardi; R Garcia-Rubio; J D Jenks; O Rivero-Menendez; R Aljohani; I D Jacobsen; J Berman; N Osherov; M T Hedayati; M Ilkit; D James-Armstrong; T Gabaldón; J Meletiadis; M Kostrzewa; W Pan; C Lass-Flörl; D S Perlin; M Hoenigl
Journal:  Stud Mycol       Date:  2021-05-10       Impact factor: 16.097

5.  Amikacin Initial Dose in Critically Ill Patients: a Nonparametric Approach To Optimize A Priori Pharmacokinetic/Pharmacodynamic Target Attainments in Individual Patients.

Authors:  Clément Boidin; Laurent Bourguignon; Sabine Cohen; Claire Roger; Jean-Yves Lefrant; Jason A Roberts; Bernard Allaouchiche; Alain Lepape; Arnaud Friggeri; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 6.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 7.  The Continued Value of Disk Diffusion for Assessing Antimicrobial Susceptibility in Clinical Laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group.

Authors:  Romney M Humphries; Susan Kircher; Andrea Ferrell; Kevin M Krause; Rianna Malherbe; Andre Hsiung; C A Burnham
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

8.  High-Dosage Cefazolin Achieves Sufficient Cerebrospinal Diffusion To Treat an External Ventricular Drainage-Related Staphylococcus aureus Ventriculitis.

Authors:  Matthieu Grégoire; Benjamin Gaborit; Colin Deschanvres; Raphaël Lecomte; Guillaume Deslandes; Éric Dailly; Xavier Ambrosi; Ronan Bellouard; Nathalie Asseray; Karim Lakhal; David Boutoille
Journal:  Antimicrob Agents Chemother       Date:  2019-01-29       Impact factor: 5.191

9.  Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated).

Authors:  Andrew Henderson; Romney Humphries
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

10.  Therapeutic Drug Monitoring of Levoffoxacin in an Obese Adolescent: A Case Report.

Authors:  Alexandra M Hanretty; Wayne S Moore; Arun Chopra; Jeffrey J Cies
Journal:  J Pediatr Pharmacol Ther       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.